title: Enhancement of differentiation induction of mouse myelomonocytic leukemic cells by extracellular ATP.
abstract: We examined the effect of ATP on the terminal differentiation of mouse myelomonocytic leukemic M1 cells to macrophages. Although ATP alone did not induce M1 cell differentiation, addition of ATP with the differentiation inducer, interleukin 6 (IL-6), enhanced the induction of differentiation by IL-6 about two-fold. Comparison among several adenine nucleotides revealed that the order of effectiveness on differentiation enhancement was ATP > ADP > AMP > or = adenosine. Using reactive blue 2, a P2 receptor antagonist, we confirmed that the effect of ATP on the stimulation of differentiation was mediated through the P2 purinergic receptor. Examination of cytosolic [Ca2+] elevation by ATP and comparison of potency of differentiation enhancement among several ATP analogs demonstrated that the effect of differentiation enhancement was mediated through P2y purinergic receptors expressed on M1 cell surface. Within 3 h of exposure, ATP alone slightly increased the expression of differentiation-related immediate early response genes, c-myc and JunB, and ATP also enhanced the IL-6-induced expression of these genes. Induction of JunB expression by ATP analogs correlated with their potency of differentiation enhancement, which suggested that induction of JunB by ATP is one of signaling pathways involved in the exertion of its differentiation-enhancing effect.
authors.affiliation: Department of Cell Biology, Chest Disease Research Institute, Kyoto, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Hirayoshi
authors.forename: M
authors.initials: M
authors.lastname: Okuma
authors.forename: K
authors.initials: K
authors.lastname: Nagata
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000199:Actins / Q000096:biosynthesis; D000241:Adenosine / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000249:Adenosine Monophosphate / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects*; D003600:Cytosol / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015850:Interleukin-6 / Q000494:pharmacology; D007700:Kinetics; D007942:Leukemia, Experimental / Q000473:pathology*; D007951:Leukemia, Myeloid / Q000473:pathology*; D051379:Mice; D010587:Phagocytosis / Q000187:drug effects; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D016755:Proto-Oncogene Proteins c-jun / Q000096:biosynthesis; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis; D011961:Receptors, Fc / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D000199:Actins; D015850:Interleukin-6; D011500:Protein Synthesis Inhibitors; D016755:Proto-Oncogene Proteins c-jun; D016271:Proto-Oncogene Proteins c-myc; D011961:Receptors, Fc; D011994:Recombinant Proteins; D014227:Triazines; D000249:Adenosine Monophosphate; C012842:Cibacron Blue F 3GA; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D000241:Adenosine; D002118:Calcium; D015056:1-Methyl-3-isobutylxanthine